CORRELATION RELATIONSHIP BETWEEN COGNITIVE DISORDERS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND BIOCHEMICAL MARKERS (CORTISOL, C-REACTIVE PROTEIN, LIPID BLOOD SPECTRUM)
Introduction. Ukraine is one of the first places in Europe in terms of mortality from diseases of the circulatory system. Materials and methods.The study included 105 patients with acute myocardial infarction and cognitive impairment under the age of 60 years. Patients were divided into three age groups: 34-40 years old, 41-50 years old, 51-60 years old, respectively. During the study, all patients had fixed levels of cortisol (depending on gender), C-reactive protein and blood lipid spectrum (atherogenicity coefficient). We evaluated the state of cognitive impairment using neuropsychological testing - Mini Mental State Examination (MMSE), a clock drawing test, the test of “remembering 10 words” by A. R. Luria.
Each group of patients was divided into 3 subgroups and 3 treatment regimens were introduced. The first treatment regimen included quercetin. In the second - quercetin + 2 ethyl-6-methyl-3-hydroxypyrimidine succinate. The third is quercetin + morpholinium 3-methyl-1,2,4-triazolin-5 thiocetam. Results. The conducted correlation analysis made it possible to obtain data and evaluate the correlation between indicators of biochemical markers (cortisol, CRP and the lipid spectrum of the blood) and cognitive impairment in patients with AMI. It was proved that in patients treated according to scheme No. 3, in different age groups on the first day of the disease and in the dynamics of treatment, an inverse correlation was established with the level of CRP, cortisol on day 10 and cognitive impairment for this period. An inverse correlation was also determined with the atherogenic coefficient at the end of treatment and the level of cognitive dysfunction at the initial stage. Conclusions. During the study, it was confirmed that when choosing treatment therapy, the effectiveness of antihypoxants and their influence on the course of cognitive disorders should be taken into account in order to restore cognitive functions in patients of working age with AMI. Starting from the first day of hospitalization, it is advisable to prescribe treatment, which leads to a regression of cognitive impairment due to high pharmacological activity (treatment regimen No. 3).
Gandzyuk V. A. Analіz zahvoryuvanostі na іshemіchnu hvorobu sercya v Ukraїnі. Ukraїns'kij kardіologіchnij zhurnal. 2014. № 3. S. 45–52.
Zaharov V. V. Diagnostika i lechenie kognitivnyh narushenij. Consilium Medicum. 2014. № 1. S. 21–27.
Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R. Heart Disease and Stroke Statistics - 2017 Update: A Report From the American Heart Association // Circulation. – 2017. - 135 (10). - e146-e603.
Kozhuhov S.N.. Nauchnye dokazatel'stva optimizacii terapii bol'nyh c hronicheskoj serdechnoj nedostatochnost'yu na fone ishemicheskoj bolezni serdca // Serceva nedostatnіst' ta komorbіdnі stani. 2017. - № 1– S. 39 – 45.
Gadzyuk V.A. Analіz zahvoryuvanostі na іshemіchnu hvorobu sercya v Ukraїnі // Ukraїns'kij kardіologіchnij zhurnal. - 2014.- № 3.- C. 45-52.
Melanie Nichols. Evropean cardiovascular disease statistics 2012 edition // Melanie Nichols, Nick Townsend, Peter Scarborough, Mike Rayner.- 2012.- S. 1-125.